p110δ PI3 kinase pathway: Emerging roles in cancer

Frontiers in Oncology

Volumn 3 MAR, Issue , 2013, Pages

  Tzenaki, Niki ^a   Papakonstanti, Evangelia A ^a  

^a UNIVERSITY OF CRETE   (Greece)

Author keywords

Cancer; Hematologic malignancies; p110 PI3K; PTEN; Solid tumors

Indexed keywords

2 (6 AMINO 9 PURINYLMETHYL) 5 METHYL 3 (2 METHYLPHENYL) 3H QUINAZOLIN 4 ONE; B LYMPHOCYTE RECEPTOR; CD40 LIGAND; CHEMOKINE RECEPTOR CXCR5; CXCL13 CHEMOKINE; DIACYLGLYCEROL; G PROTEIN COUPLED RECEPTOR; GUANOSINE TRIPHOSPHATE; IDELALISIB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PROTEIN KINASE B; PROTEIN KINASE C; PROTEIN P110; RETINOIC ACID; TOLL LIKE RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; B CELL LYMPHOMA; B LYMPHOCYTE; CELL MATURATION; GENE; GENE INACTIVATION; GLIOBLASTOMA; HODGKIN DISEASE; HUMAN; IMMUNITY; INTRACELLULAR SIGNALING; MULTIPLE MYELOMA; NEOPLASM; NEUROBLASTOMA; NONHUMAN; PHOSPHORYLATION; PIK3CA GENE; PIK3CD GENE; PROMYELOCYTIC LEUKEMIA; PROTEIN EXPRESSION; PTEN GENE; REVIEW; SIGNAL TRANSDUCTION;

EID: 84890773406     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2013.00040     Document Type: Review

References (221)

1. Aiba, Y., Kameyama, M., Yamazaki, T., Tedder, T. F., and Kurosaki, T. (2008). Regulation of B-cell development by BCAP and CD19 through their binding to phosphoinositide 3-kinase. Blood 111, 1497-1503.
2. Aksoy, E., Taboubi, S., Torres, D., Delbauve, S., Hachani, A., Whitehead, M. A., et al. (2012). The p110[delta] isoform of the kinase PI(3)K controls the subcellular compartmentalization of TLR4 signaling and protects from endotoxic shock. Nat. Immunol. 13, 1045-1054.
3. Alessi, D. R., Andjelkovic, M., Caudwell, B., Cron, P., Morrice, N., Cohen, P., et al. (1996). Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J. 15, 6541-6551.
4. Alessi, D. R., Deak, M., Casamayor, A., Caudwell, F. B., Morrice, N., Norman, D. G., et al. (1997a). 3-Phosphoinositide-dependent protein kinase-1 (PDK1): structural and functional homology with the Drosophila DSTPK61 kinase. Curr. Biol. 7, 776-789.
5. Alessi, D. R., James, S. R., Downes, C. P., Holmes, A. B., Gaffney, P. R., Reese, C. B., et al. (1997b). Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr. Biol. 7, 261-269.
6. Ali, I. U., Schriml, L. M., and Dean, M. (1999). Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity. J. Natl. Cancer Inst. 91, 1922-1932.
7. Ali, K., Bilancio, A., Thomas, M., Pearce, W., Gilfillan, A. M., Tkaczyk, C., et al. (2004). Essential role for the p110[delta] phosphoinositide 3-kinase in the allergic response. Nature 431, 1007-1011.
8. Ali, K., Camps, M., Pearce, W. P., Ji, H., Ruckle, T., Kuehn, N., et al. (2008). Isoform-specific functions of phosphoinositide 3-kinases: p110{delta} but not p110{gamma} promotes optimal allergic responses in vivo. J. Immunol. 180, 2538-2544.
9. Alvarez, B., Martinez-a, C., Burgering, B. M. T., and Carrera, A. C. (2001). Forkhead transcription factors contribute to execution of the mitotic programme in mammals. Nature 413, 744-747.
10. Arron, J. R., Vologodskaia, M., Wong, B. R., Naramura, M., Kim, N., Gu, H., et al. (2001). A positive regulatory role for Cbl family proteins in tumor necrosis factor-related activation-induced cytokine (Trance) and CD40L-mediated Akt activation. J. Biol. Chem. 276, 30011-30017.
11. Beer-Hammer, S., Zebedin, E., von Holleben, M., Alferink, J., Reis, B., Dresing, P., et al. (2010). The catalytic PI3K isoforms p110gamma and p110delta contribute to B cell development and maintenance, transformation, and proliferation. J. Leukoc. Biol. 87, 1083-1095.
12. Beitz, L. O., Fruman, D. A., Kurosaki, T., Cantley, L. C., and Scharenberg, A. M. (1999). SYK is upstream of phosphoinositide 3-kinase in B cell receptor signaling. J. Biol. Chem. 274, 32662-32666.
13. Bellacosa, A., Chan, T. O., Ahmed, N. N., Datta, K., Malstrom, S., Stokoe, D., et al. (1998). Akt activation by growth factors is a multiple-step process: the role of the PH domain. Oncogene 17, 313-325.
14. Bernards, A., and Settleman, J. (2005). GAPs in growth factor signalling. Growth Factors 23, 143-149.
15. Besson, A., Gurian-West, M., Schmidt, A., Hall, A., and Roberts, J. M. (2004). p27Kip1 modulates cell migration through the regulation of RhoA activation. Genes Dev. 18, 862-876.
16. Bi, L., Okabe, I., Bernard, D. J., and Nussbaum, R. L. (2002). Early embryonic lethality in mice deficient in the p110b catalytic subunit of PI 3-kinase. Mamm. Genome 13, 169-172.
17. Bi, L., Okabe, I., Bernard, D. J., Wynshaw-Boris, A., and Nussbaum, R. L. (1999). Proliferative defect and embryonic lethality in mice homozygous for a deletion in the p110a subunit of phosphoinositide 3-kinase. J. Biol. Chem. 274, 10963-10968.
18. Bilancio, A., Okkenhaug, K., Camps, M., Emery, J. L., Ruckle, T., Rommel, C., et al. (2006). Key role of the p110{delta} isoform of PI3K in B-cell antigen and IL-4 receptor signaling: comparative analysis of genetic and pharmacologic interference with p110{delta} function in B cells. Blood 107, 642-650.
19. Billottet, C., Banerjee, L., Vanhaesebroeck, B., and Khwaja, A. (2009). Inhibition of class I phosphoinositide 3-kinase activity impairs proliferation and triggers apoptosis in acute promyelocytic leukemia without affecting atra-induced differentiation. Cancer Res. 69, 1027-1036.
20. Billottet, C., Grandage, V. L., Gale, R. E., Quattropani, A., Rommel, C., Vanhaesebroeck, B., et al. (2006). A selective inhibitor of the p110[delta] isoform of PI 3-kinase inhibits AML cell proliferation and survival and increases the cytotoxic effects of VP16. Oncogene 25, 6648-6659.
21. Boller, D., Schramm, A., Doepfner, K. T., Shalaby, T., von Bueren, A. O., Eggert, A., et al. (2008). Targeting the phosphoinositide 3-kinase Isoform p110delta impairs growth and survival in neuroblastoma cells. Clin. Cancer Res. 14, 1172-1181.
22. Brachmann, S. M., Hofmann, I., Schnell, C., Fritsch, C., Wee, S., Lane, H., et al. (2009). Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells. Proc. Natl. Acad. Sci. U.S.A. 106, 22299-22304.
23. Brauweiler, A., Tamir, I., Dal Porto, J., Benschop, R. J., Helgason, C. D., Humphries, R. K., et al. (2000). Differential regulation of B cell development, activation, and death by the src homology 2 domain-containing 5' inositol phosphatase (SHIP). J. Exp. Med. 191, 1545-1554.
24. Buchner, M., Fuchs, S., Prinz, G., Pfeifer, D., Bartholomé, K., Burger, M., et al. (2009). Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia. Cancer Res. 69, 5424-5432.
25. Burger, J. (2012). Inhibiting B-cell receptor signaling pathways in chronic lymphocytic leukemia. Curr. Hematol. Malig. Rep. 7, 26-33.
26. Burgering, B. M. T., and Medema, R. H. (2003). Decisions on life and death: FOXO Forkhead transcription factors are in command when PKB/Akt is off duty. J. Leukoc. Biol. 73, 689-701.
27. Calvanese, V., Fernández, A. F., Urdinguio, R. G., Suárez-Alvarez, B., Mangas, C., Pérez-García, V., et al. (2012). A promoter DNA demethylation landscape of human hematopoietic differentiation. Nucleic Acids Res. 40, 116-131.
28. Campbell, I. G., Russell, S. E., Choong, D. Y. H., Montgomery, K. G., Ciavarella, M. L., Hooi, C. S. F., et al. (2004). Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res. 64, 7678-7681.
29. Castillo, J. J., Furman, M., and Winer, E. S. (2012). CAL-101: a phosphatidylinositol-3-kinase p110-delta inhibitor for the treatment of lymphoid malignancies. Expert Opin. Investig. Drugs 21, 15-22.
30. Chalhoub, N., and Baker, S. J. (2009). PTEN and the PI3-kinase pathway in cancer. Annu. Rev. Pathol. 4, 127-150.
31. Chantry, D., Vojtek, A., Kashishian, A., Holtzman, D. A., Wood, C., Gray, P. W., et al. (1997). p110delta, a novel phosphatidylinositol 3-kinase catalytic subunit that associates with p85 and is expressed predominantly in leukocytes. J. Biol. Chem. 272, 19236-19241.
32. Chapuis, N., Tamburini, J. R. M., Cornillet-Lefebvre, P., Gillot, L., Bardet, V. R., Willems, L., et al. (2010). Autocrine IGF-1/IGF-1R signaling is responsible for constitutive PI3K/Akt activation in acute myeloid leukemia: therapeutic value of neutralizing anti-IGF-1R antibody. Haematologica 95, 415-423.
33. Chen, L., Apgar, J., Huynh, L., Dicker, F., Giago-Mcgahan, T., Rassenti, L., et al. (2005). ZAP-70 directly enhances IgM signaling in chronic lymphocytic leukemia. Blood 105, 2036-2041.
34. Chen, L., Huynh, L., Apgar, J., Tang, L., Rassenti, L., Weiss, A., et al. (2008). ZAP-70 enhances IgM signaling independent of its kinase activity in chronic lymphocytic leukemia. Blood 111, 2685-2692.
35. Cheson, B. D., Bennett, J. M., Grever, M., Kay, N., Keating, M. J., O'Brien, S., et al. (1996). National cancer institute-sponsored working group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 87, 4990-4997.
36. Ciraolo, E., Iezzi, M., Marone, R., Marengo, S., Curcio, C., Costa, C., et al. (2008). Phosphoinositide 3-kinase p110beta activity: key role in metabolism and mammary gland cancer but not development. Sci. Signal. 1:ra3. doi: 10.1126/scisignal.1161577
37. Clayton, E., Bardi, G., Bell, S. E., Chantry, D., Downes, C. P., Gray, A., et al. (2002). A crucial role for the p110{delta} subunit of phosphatidylinositol 3-kinase in B cell development and activation. J. Exp. Med. 196, 753-763.
38. Condliffe, A. M., Davidson, K., Anderson, K. E., Ellson, C. D., Crabbe, T., Okkenhaug, K., et al. (2005). Sequential activation of class IB and class IA PI3K is important for the primed respiratory burst of human but not murine neutrophils. Blood 106, 1432-1440.
39. Contri, A., Brunati, A., Trentin, L., Cabrelle, A., Miorin, M., Cesaro, L., et al. (2005). Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis. J. Clin. Invest. 115, 369-378.
40. Cornillet-Lefebvre, P., Cuccuini, W., Bardet, V., Tamburini, J., Gillot, L., Ifrah, N., et al. (2005). Constitutive phosphoinositide 3-kinase activation in acute myeloid leukemia is not due to p110[delta] mutations. Leukemia 20, 374-376.
41. Cortés, I., Sánchez-Ruíz, J., Zuluaga, S., Calvanese, V., Marqués, M., Hernández, C., et al. (2012). p85ß phosphoinositide 3-kinase subunit regulates tumor progression. Proc. Natl. Acad. Sci. U.S.A. 109, 11318-11323.
42. Cully, M., You, H., Levine, A. J., and Mak, T. W. (2006). Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat. Rev. Cancer 6, 184-192.
43. Currie, R. A., Walker, K. S., Gray, A., Deak, M., Casamayor, A., Downes, C. P., et al. (1999). Role of phosphatidylinositol 3, 4, 5-trisphosphate in regulating the activity and localization of 3-phosphoinositide-dependent protein kinase-1. Biochem. J. 337, 575-583.
44. Datta, S. R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y., et al. (1997). Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91, 231-241.
45. Delgado, P., Cubelos, B., Calleja, E., Martinez-Martin, N., Cipres, A., Merida, I., et al. (2009). Essential function for the GTPase TC21 in homeostatic antigen receptor signaling. Nat. Immunol. 10, 880-888.
46. De Rooij, M. F. M., Kuil, A., Geest, C. R., Eldering, E., Chang, B. Y., Buggy, J. J., et al. (2012). The clinically active BTK inhibitor PCI-32765 targets B-cell receptor-and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood 119, 2590-2594.
47. Di Nicolantonio, F., Arena, S., Tabernero, J., Grosso, S., Molinari, F., Macarulla, T., et al. (2010). Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J. Clin. Invest. 120, 2858-2866.
48. Doepfner, K. T., Spertini, O., and Arcaro, A. (2007). Autocrine insulin-like growth factor-I signaling promotes growth and survival of human acute myeloid leukemia cells via the phosphoinositide 3-kinase/Akt pathway. Leukemia 21, 1921-1930.
49. Durand, C. A., Hartvigsen, K., Fogelstrand, L., Kim, S., Iritani, S., Vanhaesebroeck, B., et al. (2009). Phosphoinositide 3-kinase p110 delta regulates natural antibody production, marginal zone and B-1 B cell function, and autoantibody responses. J. Immunol. 183, 5673-5684.
50. Edgar, K. A., Wallin, J. J., Berry, M., Lee, L. B., Prior, W. W., Sampath, D., et al. (2010). Isoform-specific phosphoinositide 3-kinase inhibitors exert distinct effects in solid tumors. Cancer Res. 70, 1164-1172.
51. Edwards, H., Xie, C., Lafiura, K. M., Dombkowski, A. A., Buck, S. A., Boerner, J. L., et al. (2009). RUNX1 regulates phosphoinositide 3-kinase/AKT pathway: role in chemotherapy sensitivity in acute megakaryocytic leukemia. Blood 114, 2744-2752.
52. Efremov, D., and Laurenti, L. (2011). The Syk kinase as a therapeutic target in leukemia and lymphoma. Expert. Opin. Investig. Drugs 20, 623-636.
53. Eickholt, B. J., Ahmed, A. I., Davies, M., Papakonstanti, E. A., Pearce, W., Starkey, M. L., et al. (2007). Control of axonal growth and regeneration of sensory neurons by the p110d PI 3-kinase. PLoS ONE 2:e869. doi: 10.1371/journal.pone.0000869
54. Engelman, J. A., Luo, J., and Cantley, L. C. (2006). The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat. Rev. Genet. 7, 606-619.
55. Fine, B., Hodakoski, C., Koujak, S., Su, T., Saal, L. H., Maurer, M., et al. (2009). Activation of the PI3K pathway in cancer through inhibition of PTEN by exchange factor P-REX2a. Science 325, 1261-1265.
56. Foukas, L. C., Berenjeno, I. M., Gray, A., Khwaja, A., and Vanhaesebroeck, B. (2010). Activity of any class IA PI3K isoform can sustain cell proliferation and survival. Proc. Natl. Acad. Sci. U.S.A. 107, 11381-11386.
57. Foukas, L. C., Claret, M., Pearce, W., Okkenhaug, K., Meek, S., Peskett, E., et al. (2006). Critical role for the p110[alpha] phosphoinositide-3-OH kinase in growth and metabolic regulation. Nature 441, 366-370.
58. Fruman, D. A. (2004). Phosphoinositide 3-kinase and its targets in B-cell and T-cell signaling. Curr. Opin. Immunol. 16, 314-320.
59. Fruman, D. A., and Rommel, C. (2011). PI3Kd inhibitors in cancer: rationale and serendipity merge in the clinic. Cancer Discov. 1, 562-572.
60. Fujimoto, M., Fujimoto, Y., Poe, J. C., Jansen, P. J., Lowell, C. A., Defranco, A. L., et al. (2000). CD19 regulates Src family protein tyrosine kinase activation in B lymphocytes through processive amplification. Immunity 13, 47-57.
61. Fujita, N., Sato, S., Katayama, K., and Tsuruo, T. (2002). Akt-dependent phosphorylation of p27Kip1 promotes binding to 14-3-3 and cytoplasmic localization. J. Biol. Chem. 277, 28706-28713.
62. Garami, A., Zwartkruis, F. J. T., Nobukuni, T., Joaquin, M., Roccio, M., Stocker, H., et al. (2003). Insulin activation of rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. Mol. Cell 11, 1457-1466.
63. Geering, B., Cutillas, P. R., Nock, G., Gharbi, S. I., and Vanhaesebroeck, B. (2007). Class IA phosphoinositide 3-kinases are obligate p85-p110 heterodimers. Proc. Natl. Acad. Sci. U.S.A. 104, 7809-7814.
64. Georgakis, G. V., Li, Y., Rassidakis, G. Z., Medeiros, L. J., Mills, G. B., and Younes, A. (2006). Inhibition of the phosphatidylinositol-3 kinase/Akt promotes G1 cell cycle arrest and apoptosis in Hodgkin lymphoma. Br. J. Haematol. 132, 503-511.
65. Gobessi, S., Laurenti, L., Longo, P. G., Sica, S., Leone, G., and Efremov, D. G. (2007). ZAP-70 enhances B-cell-receptor signaling despite absent or inefficient tyrosine kinase activation in chronic lymphocytic leukemia and lymphoma B cells. Blood 109, 2032-2039.
66. Graupera, M., Guillermet-Guibert, J., Foukas, L. C., Phng, L.-K., Cain, R. J., Salpekar, A., et al. (2008). Angiogenesis selectively requires the p110[alpha] isoform of PI3K to control endothelial cell migration. Nature 453, 662-666.
67. Grønbæk, K., Zeuthen, J., Guldberg, P., Ralfkiaer, E., and Hou-Jensen, K. (1998). Alterations of the MMAC1/PTEN gene in lymphoid malignancies. Blood 91, 4388-4390.
68. Guillermet-Guibert, J., Bjorklof, K., Salpekar, A., Gonella, C., Ramadani, F., Bilancio, A., et al. (2008). The p110b isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110g. Proc. Natl. Acad. Sci. U.S.A. 105, 8292-8297.
69. Gymnopoulos, M., Elsliger, M.-A., and Vogt, P. K. (2007). Rare cancer-specific mutations in PIK3CA show gain of function. Proc. Natl. Acad. Sci. U.S.A. 104, 5569-5574.
70. Hallek, M., Cheson, B. D., Catovsky, D., Caligaris-Cappio, F., Dighiero, G., Döhner, H., et al. (2008). Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111, 5446-5456.
71. Hawkins, P. T., Anderson, K. E., Davidson, K., and Stephens, L. R. (2006). Signalling through Class I PI3Ks in mammalian cells. Biochem. Soc. Trans. 34, 647-662.
72. Hayakawa, M., Kawaguchi, K.-I., Kaizawa, H., Koizumi, T., Ohishi, T., Yamano, M., et al. (2007). Synthesis and biological evaluation of sulfonylhydrazone-substituted imidazo[1, 2-a]pyridines as novel PI3 kinase p110alpha inhibitors. Bioorg. Med. Chem. 15, 5837-5844.
73. Henley, T., Kovesdi, D., and Turner, M. (2008). B-cell responses to B-cell activation factor of the TNF family (BAFF) are impaired in the absence of PI3K delta. Eur. J. Immunol. 38, 3543-3548.
74. Herman, S. E. M., Gordon, A. L., Hertlein, E., Ramanunni, A., Zhang, X., Jaglowski, S., et al. (2011). Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood 117, 6287-6296.
75. Herman, S. E. M., Gordon, A. L., Wagner, A. J., Heerema, N. A., Zhao, W., Flynn, J. M., et al. (2010). Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood 116, 2078-2088.
76. Hill, K., Welti, S., Yu, J., Murray, J. T., Yip, S.-C., Condeelis, J. S., et al. (2000). Specific requirement for the p85-p110alpha phosphatidylinositol 3-kinase during epidermal growth factor-stimulated actin nucleation in breast cancer cells. J. Biol. Chem. 275, 3741-3744.
77. Hoellenriegel, J., Meadows, S. A., Sivina, M., Wierda, W. G., Kantarjian, H., Keating, M. J., et al. (2011). The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood 118, 3603-3612.
78. Hooshmand-Rad, R., Hajkova, L., Klint, P., Karlsson, R., Vanhaesebroeck, B., Claesson-Welsh, L., et al. (2000). The PI 3-kinase isoforms p110a and p110b have differential roles in PDGF-and insulin-mediated signaling. J. Cell Sci. 113, 207-214.
79. Hu, P., Mondino, A., Skolnik, E. Y., and Schlessinger, J. (1993). Cloning of a novel ubiquitously expressed human phosphatidylinositol 3-kinase and identification of its binding site on p85. Mol. Cell. Biol. 13, 7677-7688.
80. Ihle, N. T., Lemos, R., Wipf, P., Yacoub, A., Mitchell, C., Siwak, D., et al. (2009). Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic ras is a dominant predictor for resistance. Cancer Res. 69, 143-150.
81. Ikeda, H., Hideshima, T., Fulciniti, M., Perrone, G., Miura, N., Yasui, H., et al. (2010). PI3K/p110delta is a novel therapeutic target in multiple myeloma. Blood 116, 1460-1468.
82. Inoki, K., Li, Y., Xu, T., and Guan, K.-L. (2003). Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev. 17, 1829-1834.
83. Ismail, S. I., Mahmoud, I. S., Msallam, M. M., and Sughayer, M. A. (2010). Hotspot mutations of PIK3CA and AKT1 genes are absent in multiple myeloma. Leuk. Res. 34, 824-826.
84. Jackson, S. P., Schoenwaelder, S. M., Goncalves, I., Nesbitt, W. S., Yap, C. L., Wright, C. E., et al. (2005). PI 3-kinase p110b: a new target for antithrombotic therapy. Nat. Med. 11, 507.
85. Jia, S., Liu, Z., Zhang, S., Liu, P., Zhang, L., Lee, S. H., et al. (2008). Essential roles of PI(3)K-p110ß in cell growth, metabolism and tumorigenesis. Nature 454, 776-779.
86. Jia, S., Roberts, T. M., and Zhao, J. J. (2009). Should individual PI3 kinase isoforms be targeted in cancer? Curr. Opin. Cell Biol. 21, 199-208.
87. Jiang, X., Chen, S., Asara, J. M., and Balk, S. P. (2010). Phosphoinositide 3-kinase pathway activation in Phosphate and Tensin Homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110b and p110d catalytic subunits. J. Biol. Chem. 285, 14980-14989.
88. Jimenez, C., Hernandez, C., Pimentel, B., and Carrera, A. C. (2002). The p85 regulatory subunit controls sequential activation of phosphoinositide 3-kinase by Tyr kinases and Ras. J. Biol. Chem. 277, 41556-41562.
89. Jope, R. S., and Johnson, G. V. W. (2004). The glamour and gloom of glycogen synthase kinase-3. Trends Biochem. Sci. 29, 95-102.
90. Jou, S.-T., Carpino, N., Takahashi, Y., Piekorz, R., Chao, J.-R., Carpino, N., et al. (2002). Essential, nonredundant role for the phosphoinositide 3-kinase p110d in signaling by the B-Cell receptor complex. Mol. Cell. Biol. 22, 8580-8591.
91. Kang, S., Denley, A., Vanhaesebroeck, B., and Vogt, P. K. (2006). Oncogenic transformation induced by the p110beta,-{gamma}, and-{delta} isoforms of class I phosphoinositide 3-kinase. Proc. Natl. Acad. Sci. U.S.A. 103, 1289-1294.
92. Kim, N., Saudemont, A., Webb, L., Camps, M., Ruckle, T., Hirsch, E., et al. (2007). The p110delta catalytic isoform of PI3K is a key player in NK-cell development and cytokine secretion. Blood 110, 3202-3208.
93. Klarlund, J., Guilherme, A., Holik, J., Virbasius, J., Chawla, A., and Czech, M. (1997). Signaling by phosphoinositide-3, 4, 5-trisphosphate through proteins containing pleckstrin and Sec7 homology domains. Science 275, 1927-1930.
94. Knobbe, C. B., and Reifenberger, G. (2003). Genetic alterations and aberrant expression of genes related to the phosphatidyl-inositol-3'-kinase/protein kinase B (Akt) signal transduction pathway in glioblastomas. Brain Pathol. 13, 507-518.
95. Kok, K., Geering, B., and Vanhaesebroeck, B. (2009a). Regulation of phosphoinositide 3-kinase expression in health and disease. Trends Biochem. Sci. 34, 115-127.
96. Kok, K., Nock, G. E., Verrall, E. A. G., Mitchell, M. P., Hommes, D. W., Peppelenbosch, M. P., et al. (2009b). Regulation of p110d PI 3-kinase gene expression. PLoS ONE 4:e5145. doi: 10.1371/journal.pone.0005145
97. Krugmann, S., Cooper, M. A., Williams, D. H., Hawkins, P. T., and Stephens, L. R. (2002). Mechanism of the regulation of type IB phosphoinositide 3OH-kinase by G-protein bg subunits. Biochem. J. 362, 725-731.
98. Krugmann, S., Hawkins, P. T., Pryer, N., and Braselmann, S. (1999). Characterizing the interactions between the two subunits of the p101/p110gamma phosphoinositide 3-kinase and their role in the activation of this enzyme by G beta gamma subunits. J. Biol. Chem. 274, 17152-17158.
99. Kurosaki, T., Takata, M., Yamanashi, Y., Inazu, T., Taniguchi, T., Yamamoto, T., et al. (1994). Syk activation by the Src-family tyrosine kinase in the B cell receptor signaling. J. Exp. Med. 179, 1725-1729.
100. Lal, L., Li, Y., Smith, J., Sassano, A., Uddin, S., Parmar, S., et al. (2005). Activation of the p70 S6 kinase by all-trans-retinoic acid in acute promyelocytic leukemia cells. Blood 105, 1669-1677.
101. Lannutti, B. J., Meadows, S. A., Herman, S. E. M., Kashishian, A., Steiner, B., Johnson, A. J., et al. (2011). CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood 117, 591-594.
102. Lehmann, B. D., Bauer, J. A., Chen, X., Sanders, M. E., Chakravarthy, A. B., Shyr, Y., et al. (2011). Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J. Clin. Invest. 121, 2750-2767.
103. Lenz, G., Wright, G. W., Emre, N. C. T., Kohlhammer, H., Dave, S. S., Davis, R. E., et al. (2008). Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc. Natl. Acad. Sci. U.S.A. 105, 13520-13525.
104. Leslie, N. R., and Downes, C. P. (2002). PTEN: the down side of PI 3-kinase signalling. Cell. Signal. 14, 285-295.
105. Leslie, N. R., and Downes, C. P. (2004). PTEN function: how normal cells control it and tumour cells lose it. Biochem. J. 382, 1-11.
106. Leupin, N., Cenni, B., Novak, U., Hügli, B., Graber, H. U., Tobler, A., et al. (2003). Disparate expression of the PTEN gene: a novel finding in B-cell chronic lymphocytic leukaemia (B-CLL). Br. J. Haematol. 121, 97-100.
107. Leverrier, Y., Okkenhaug, K., Sawyer, C., Bilancio, A., Vanhaesebroeck, B., and Ridley, A. J. (2003). Class I phosphoinositide 3-kinase p110beta is required for apoptotic cell and Fcgamma receptor-mediated phagocytosis by macrophages. J. Biol. Chem. 278, 38437-38442.
108. Li, Y., Corradetti, M. N., Inoki, K., and Guan, K.-L. (2004). TSC2: filling the GAP in the mTOR signaling pathway. Trends Biochem. Sci. 29, 32-38.
109. Liang, J., and Slingerland, J. M. (2003). Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle 2, 336-342.
110. Liang, J., Zubovitz, J., Petrocelli, T., Kotchetkov, R., Connor, M. K., Han, K., et al. (2002). PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nat. Med. 8, 1153-1160.
111. Low, P. C., Misaki, R., Schroder, K., Stanley, A. C., Sweet, M. J., Teasdale, R. D., et al. (2010). Phosphoinositide 3-kinase d regulates membrane fission of Golgi carriers for selective cytokine secretion. J. Cell Biol. 190, 1053-1065.
112. Luo, J., Manning, B. D., and Cantley, L. C. (2003). Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 4, 257-262.
113. Ma, S., and Rosen, S. T. (2011). Signal transduction inhibitors in chronic lymphocytic leukemia. Curr. Opin. Oncol. 23, 601-608.
114. Maehama, T., and Dixon, J. E. (1998). The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3, 4, 5-trisphosphate. J. Biol. Chem. 273, 13375-13378.
115. Manning, B. D., and Cantley, L. C. (2007). AKT/PKB signaling: navigating downstream. Cell 129, 1261-1274.
116. Marinov, M., Fischer, B., and Arcaro, A. (2007). Targeting mTOR signaling in lung cancer. Crit. Rev. Oncol. Hematol. 63, 172-182.
117. Marone, R., Cmiljanovic, V., Giese, B., and Wymann, M. P. (2008). Targeting phosphoinositide 3-kinase-moving towards therapy. Biochim. Biophys. Acta 1784, 159-185.
118. Martins, L., Lúcio, P., Silva, M., Gameiro, P., Silva, M., and Barata, J. (2011). On CK2 regulation of chronic lymphocytic leukemia cell viability. Mol. Cell. Biochem. 356, 51-55.
119. Meadows, S. A., Vega, F., Kashishian, A., Johnson, D., Diehl, V., Miller, L. L., et al. (2012). PI3Kdelta inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma. Blood 119, 1897-1900.
120. Meric-Bernstam, F., Akcakanat, A., Chen, H., Do, K.-A., Sangai, T., Adkins, F., et al. (2012). PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors. Clin. Cancer Res. 18, 1777-1789.
121. Meuillet, E., Zuohe, S., Lemos, R., Ihle, N., Kingston, J., Watkins, R., et al. (2010). Molecular pharmacology and antitumor activity of PHT-427, a novel Akt/phosphatidylinositide-dependent protein kinase 1 pleckstrin homology domain inhibitor. Mol. Cancer Ther. 9, 706-717.
122. Min, Y. H., Eom, J. I., Cheong, J. W., Maeng, H. O., Kim, J. Y., Jeung, H. K., et al. (2003). Constitutive phosphorylation of Akt//PKB protein in acute myeloid leukemia: its significance as a prognostic variable. Leukemia 17, 995-997.
123. Mizoguchi, M., Nutt, C. L., Mohapatra, G., and Louis, D. N. (2004). Genetic alterations of phosphoinositide 3-kinase subunit genes in human glioblastomas. Brain Pathol. 14, 372-377.
124. Ni, M., Macfarlane, A. W., Toft, M., Lowell, C. A., Campbell, K. S., and Hamerman, J. A. (2012). B-cell adaptor for PI3K (BCAP) negatively regulates Toll-like receptor signaling through activation of PI3K. Proc. Natl. Acad. Sci. U.S.A. 109, 267-272.
125. Norman, P. (2011). Selective PI3Kd inhibitors, a review of the patent literature. Expert. Opin. Ther. Pat 21, 1773-1790.
126. O'Brien, C., Wallin, J. J., Sampath, D., Guhathakurta, D., Savage, H., Punnoose, E. A., et al. (2010). Predictive biomarkers of sensitivity to the phosphatidylinositol 3 kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin. Cancer Res. 16, 3670-3683.
127. Okada, T., Maeda, A., Iwamatsu, A., Gotoh, K., and Kurosaki, T. (2000). BCAP: the tyrosine kinase substrate that connects B cell receptor to phosphoinositide 3-kinase activation. Immunity 13, 817-827.
128. Okkenhaug, K., Bilancio, A., Farjot, G., Priddle, H., Sancho, S., Peskett, E., et al. (2002). Impaired B and T cell antigen receptor signaling in p110d PI 3-kinase mutant mice. Science 297, 1031-1034.
129. Okkenhaug, K., and Fruman, D. A. (2010). PI3Ks in lymphocyte signaling and development. Curr. Top. Microbiol. Immunol. 346, 57-85.
130. Papakonstanti, E. A., Emmanouel, D. S., Gravanis, A., and Stournaras, C. (2000). PLC-gamma1 signaling pathway and villin activation are involved in actin cytoskeleton reorganization induced by Na+/Pi cotransport up-regulation. Mol. Med. 6, 303-318.
131. Papakonstanti, E. A., Ridley, A. J., and Vanhaesebroeck, B. (2007). The p110d isoform of PI 3-kinase negatively controls RhoA and PTEN. EMBO J. 26, 3050-3061.
132. Papakonstanti, E. A., Zwaenepoel, O., Bilancio, A., Burns, E., Nock, G. E., Houseman, B., et al. (2008). Distinct roles of class IA PI 3-kinase isoforms in primary and immortalised macrophages. J. Cell Sci. 121, 4124-4133.
133. Parsons, D. W., Jones, S., Zhang, X., Lin, J. C., Leary, R. J., Angenendt, P., et al. (2008). An integrated genomic analysis of human glioblastoma multiforme. Science 321, 1807-1812.
134. Parsons, R. (2004). Human cancer, PTEN and the PI-3 kinase pathway. Semin. Cell Dev. Biol. 15, 171-176.
135. Patke, A., Mecklenbrauker, I., Erdjument-Bromage, H., Tempst, P., and Tarakhovsky, A. (2006). BAFF controls B cell metabolic fitness through a PKC beta-and Akt-dependent mechanism. J. Exp. Med. 203, 2551-2562.
136. Patton, D. T., Garden, O. A., Pearce, W. P., Clough, L. E., Monk, C. R., Leung, E., et al. (2006). Cutting edge: the phosphoinositide 3-kinase p110d is critical for the function of CD4+CD25+Foxp3+ regulatory T cells. J. Immunol. 177, 6598-6602.
137. Pauls, S. D., Lafarge, S. T., Landego, I., Zhang, T., and Marshall, A. J. (2012). The phosphoinositide 3-kinase signalling pathway in normal and malignant B cells: activation mechanisms, regulation and impact on cellular functions. Front. Immunol. 3:224. doi: 10.3389/fimmu.2012.00224
138. Peso, L. D., González-García, M., Page, C., Herrera, R., and Nuñez, G. (1997). Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 278, 687-689.
139. Philipp-Staheli, J., Payne, S. R., and Kemp, C. J. (2001). p27Kip1: regulation and function of a haploinsufficient tumor suppressor and its misregulation in cancer. Exp. Cell Res. 264, 148-168.
140. Ponader, S., Chen, S.-S., Buggy, J. J., Balakrishnan, K., Gandhi, V., Wierda, W. G., et al. (2012). The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood 119, 1182-1189.
141. Pullen, N., Dennis, P. B., Andjelkovic, M., Dufner, A., Kozma, S. C., Hemmings, B. A., et al. (1998). Phosphorylation and activation of p70S6K by PDK1. Science 279, 707-710.
142. Puri, K. D., and Gold, M. R. (2012). Selective inhibitors of phosphoinositide 3-kinase delta: modulators of B-cell function with potential for treating autoimmune inflammatory diseases and B-cell malignancies. Front. Immunol. 3:256. doi: 10.3389/fimmu.2012.00256
143. Putz, E. M., Prchal-Murphy, M., Simma, O. A., Forster, F., Koenig, X., Stockinger, H., et al. (2012). PI3Kdelta is essential for tumor clearance mediated by cytotoxic T lymphocytes. PLoS ONE 7:e40852. doi: 10.1371/journal.pone.0040852
144. Ramadani, F., Bolland, D. J., Garcon, F., Emery, J. L., Vanhaesebroeck, B., Corcoran, A. E., et al. (2010). The PI3K isoforms p110{alpha} and p110{delta} are essential for Pre-B cell receptor signaling and B cell development. Sci. Signal. 3:ra60. doi: 10.1126/scisignal.2001104
145. Rao, E., Jiang, C., Ji, M., Huang, X., Iqbal, J., Lenz, G., et al. (2012). The miRNA-17[sim]92 cluster mediates chemoresistance and enhances tumor growth in mantle cell lymphoma via PI3K/AKT pathway activation. Leukemia 26, 1064-1072.
146. Reif, K., Okkenhaug, K., Sasaki, T., Penninger, J. M., Vanhaesebroeck, B., and Cyster, J. G. (2004). Cutting edge: differential roles for phosphoinositide 3-kinases, p110gamma and p110delta, in lymphocyte chemotaxis and homing. J. Immunol. 173, 2236-2240.
147. Reth, M. (1992). Antigen receptors on B lymphocytes. Annu. Rev. Immunol. 10, 97-121.
148. Ridley, A. J., Schwartz, M. A., Burridge, K., Firtel, R. A., Ginsberg, M. H., Borisy, G., et al. (2003). Cell migration: integrating signals from front to back. Science 302, 1704-1709.
149. Roche, S., Downward, J., Raynal, P., and Courtneidge, S. A. (1998). A function for phosphatidylinositol 3-kinase beta (p85alpha-p110beta) in fibroblasts during mitogenesis: requirement for insulin-and lysophosphatidic acid-mediated signal transduction. Mol. Cell. Biol. 18, 7119-7129.
150. Roche, S., Koegl, M., and Courtneidge, S. A. (1994). The phosphatidylinositol 3-kinase alpha is required for DNA synthesis induced by some, but not all, growth factors. Proc. Natl. Acad. Sci. U.S.A. 91, 9185-9189.
151. Rodriguez-Viciana, P., Warne, P. H., Dhand, R., Vanhaesebroeck, B., Gout, I., Fry, M. J., et al. (1994). Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 370, 527-532.
152. Rommel, C. (2010). Taking PI3Kd and PI3K? one step ahead: dual active PI3Kd/? inhibitors for the treatment of immune-mediated inflammatory diseases. Curr. Top. Microbiol. Immunol. 346, 279-299.
153. Rommel, C., Camps, M., and Ji, H. (2007). PI3K[delta] and PI3K[gamma]: partners in crime in inflammation in rheumatoid arthritis and beyond? Nat. Rev. Immunol. 7, 191-201.
154. Rosenwald, A., Alizadeh, A. A., Widhopf, G., Simon, R., Davis, R. E., Yu, X., et al. (2001). Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J. Exp. Med. 194, 1639-1648.
155. Sabbah, D. A., Brattain, M. G., and Zhong, H. (2011). Dual inhibitors of PI3K/mTOR or mTOR-selective inhibitors: which way shall we go? Curr. Med. Chem. 18, 5528-5544.
156. Sadhu, C., Masinovsky, B., Dick, K., Sowell, C. G., and Staunton, D. E. (2003). Essential role of phosphoinositide 3-kinase d in neutrophil directional movement. J. Immunol. 170, 2647-2654.
157. Sáez, A. L., Sánchez, E., Sánchez-Beato, M., Cruz, M. A., Chacón, I., Muñoz, E., et al. (1999). p27Kip1 is abnormally expressed in Diffuse Large B-Cell Lymphomas and is associated with an adverse clinical outcome. Br. J. Cancer 80, 1427-1434.
158. Sakai, A., Thieblemont, C., Wellmann, A., Jaffe, E. S., and Raffeld, M. (1998). PTEN gene alterations in lymphoid neoplasms. Blood 92, 3410-3415.
159. Samuels, Y., and Velculescu, V. E. (2004). Oncogenic mutations of PIK3CA in human cancers. Cell Cycle 3, 1221-1224.
160. Sanchez, C., Ma, C., Crowder, R., Guintoli, T., Phommaly, C., Gao, F., et al. (2011). Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer. Breast Cancer Res. 13:R21. doi: 10.1186/bcr2833
161. Sansal, I., and Sellers, W. R. (2004). The biology and clinical relevance of the PTEN tumor suppressor pathway. J. Clin. Oncol. 22, 2954-2963.
162. Santiskulvong, C., Konecny, G. E., Fekete, M., Chen, K.-Y. M., Karam, A., Mulholland, D., et al. (2011). Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma. Clin. Cancer Res. 17, 2373-2384.
163. Sarbassov, D., Guertin, D., Ali, S., and Sabatini, D. (2005). Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307, 1098-1101.
164. Sasaki, T., Irie-Sasaki, J., Jones, R. G., Oliveira-Dos-Santos, A. J., Stanford, W. L., Bolon, B., et al. (2000). Function of PI3Kg in thymocyte development, T cell activation, and neutrophil migration. Science 287, 1040-1046.
165. Saudemont, A., Okkenhaug, K., and Colucci, F. (2007). p110d is required for innate immunity to transplantable lymphomas. Biochem. Soc. Trans. 35, 183-185.
166. Sawyer, C., Sturge, J., Bennett, D. C., O'Hare, M. J., Allen, W. E., Bain, J., et al. (2003). Regulation of breast cancer cell chemotaxis by the phosphoinositide 3-kinase p110delta. Cancer Res. 63, 1667-1675.
167. Schmid, M. C., Avraamides, C. J., Dippold, H. C., Franco, I., Foubert, P., Ellies, L. G., et al. (2011). Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3K3, a single convergent point promoting tumor inflammation and progression. Cancer Cell 19, 715-727.
168. Sharman, J., De Vos, S., Leonard, J. P., Furman, R. R., Coutre, S. E., Flinn, I. W., et al. (2011). A phase 1 study of the selective phosphatidylinositol 3-kinase delta (PI3K delta) inhibitor, CAL-101 (GS-1101), in combination with rituximab and/or bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). Blood 118, 779-780.
169. She, Q.-B., Chandarlapaty, S., Ye, Q., Lobo, J., Haskell, K. M., Leander, K. R., et al. (2008). Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling. PLoS ONE 3:e3065. doi: 10.1371/journal.pone.0003065
170. Shehata, M., Schnabl, S., Demirtas, D., Hilgarth, M., Hubmann, R., Ponath, E., et al. (2010). Reconstitution of PTEN activity by CK2 inhibitors and interference with the PI3-K/Akt cascade counteract the antiapoptotic effect of human stromal cells in chronic lymphocytic leukemia. Blood 116, 2513-2521.
171. Sheppard, K., Kinross, K. M., Solomon, B., Pearson, R. B., and Phillips, W. A. (2012). Targeting PI3 kinase/AKT/mTOR signaling in cancer. Crit. Rev. Oncog. 17, 69-95.
172. Slingerland, J. P. (2000). Regulation of the Cdk inhibitor p27 and its deregulation in cancer. J. Cell. Physiol. 183, 10-17.
173. So, L., and Fruman, D. A. (2012). PI3K signalling in B-and T-lymphocytes: new developments and therapeutic advances. Biochem. J. 442, 465-481.
174. Soond, D. R., Bjørgo, E., Moltu, K., Dale, V. Q., Patton, D. T., Torgersen, K. M., et al. (2010). PI3K p110delta regulates T-cell cytokine production during primary and secondary immune responses in mice and humans. Blood 115, 2203-2213.
175. Spaargaren, M., Beuling, E. A., Rurup, M. L., Meijer, H. P., Klok, M. D., Middendorp, S., et al. (2003). The B cell antigen receptor controls integrin activity through Btk and PLCgamma2. J. Exp. Med. 198, 1539-1550.
176. Stambolic, V., Suzuki, A., Delapompa, J. L., Brothers, G. M., Mirtsos, C., Sasaki, T., et al. (1998). Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 95, 29-39.
177. Stemke-Hale, K., Gonzalez-Angulo, A. M., Lluch, A., Neve, R. M., Kuo, W.-L., Davies, M., et al. (2008). An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res. 68, 6084-6091.
178. Stephens, L., Anderson, K., Stokoe, D., Erdjument-Bromage, H., Painter, G. F., Holmes, A. B., et al. (1998). Protein kinase B kinases that mediate phosphatidylinositol 3, 4, 5-trisphosphate-dependent activation of protein kinase B. Science 279, 710-714.
179. Stephens, L. R., Eguinoa, A., Erdjument-Bromage, H., Lui, M., Cooke, F., Coadwell, J., et al. (1997). The G beta gamma sensitivity of a PI3K is dependent upon a tightly associated adaptor, p101. Cell 89, 105-114.
180. Stokoe, D., Stephens, L. R., Copeland, T., Gaffney, P. R., Reece, C. B., Painter, G. F., et al. (1997). Dual role of phosphatidylinositol-3, 4, 5-trisphosphate in the activation of protein kinase B. Science 277, 567-570.
181. Suire, S., Coadwell, J., Ferguson, G. J., Davidson, K., Hawkins, P., and Stephens, L. (2005). p84, a new Gbetagamma-activated regulatory subunit of the type IB phosphoinositide 3-kinase p110gamma. Curr. Biol. 15, 566-570.
182. Sujobert, P., Bardet, V., Cornillet-Lefebvre, P., Hayflick, J. S., Prie, N., Verdier, F., et al. (2005). Essential role for the p110{delta} isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia. Blood 106, 1063-1066.
183. Sulis, M. L., and Parsons, R. (2003). PTEN: from pathology to biology. Trends Cell Biol. 13, 478-483.
184. Tanaka, H., Yoshida, M., Tanimura, H., Fujii, T., Sakata, K., Tachibana, Y., et al. (2011). The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations. Clin. Cancer Res. 17, 3272-3281.
185. Tazzari, P. L., Tabellini, G., Bortul, R., Papa, V., Evangelisti, C., Grafone, T., et al. (2007). The insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 induces apoptosis in acute myeloid leukemia cells exhibiting autocrine insulin-like growth factor-I secretion. Leukemia 21, 886-896.
186. Teschendorff, A. E., Journée, M., Absil, P. A., Sepulchre, R., and Caldas, C. (2007). Elucidating the altered transcriptional programs in breast cancer using independent component analysis. PLoS Comput. Biol. 3:e161. doi: 10.1371/journal.pcbi.0030161
187. TGCA. (2008). Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061-1068.
188. Thomas, R. K., Baker, A. C., Debiasi, R. M., Winckler, W., Laframboise, T., Lin, W. M., et al. (2007). High-throughput oncogene mutation profiling in human cancer. Nat. Genet. 39, 347-351.
189. Torbett, N. E., Luna-Moran, A., Knight, Z. A., Houk, A., Moasser, M., Weiss, W., et al. (2008). A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition. Biochem. J. 415, 97-110.
190. Torres, J., and Pulido, R. (2001). The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus. J. Biol. Chem. 276, 993-998.
191. Trentin, L., Frasson, M., Donella-Deana, A., Frezzato, F., Pagano, M. A., Tibaldi, E., et al. (2008). Geldanamycin-induced Lyn dissociation from aberrant Hsp90-stabilized cytosolic complex is an early event in apoptotic mechanisms in B-chronic lymphocytic leukemia. Blood 112, 4665-4674.
192. Troutman, T. D., Hu, W., Fulenchek, S., Yamazaki, T., Kurosaki, T., Bazan, J. F., et al. (2012). Role for B-cell adapter for PI3K (BCAP) as a signaling adapter linking Toll-like receptors (TLRs) to serine/threonine kinases PI3K/Akt. Proc. Natl. Acad. Sci. U.S.A. 109, 273-278.
193. Tuveson, D., Carter, R., Soltoff, S., and Fearon, D. (1993). CD19 of B cells as a surrogate kinase insert region to bind phosphatidylinositol 3-kinase. Science 260, 986-989.
194. Tzenaki, N., Andreou, M., Stratigi, K., Vergetaki, A., Makrigiannakis, A., Vanhaesebroeck, B., et al. (2012). High levels of p110d PI3K expression in solid tumor cells suppresses PTEN activity, generating cellular sensitivity to p110d inhibitors through PTEN activation. FASEB J. 26, 2498-2508.
195. Vanhaesebroeck, B., Ali, K., Bilancio, A., Geering, B., and Foukas, L. C. (2005). Signalling by PI3K isoforms: insights from gene-targeted mice. Trends Biochem. Sci. 30, 194-204.
196. Vanhaesebroeck, B., Guillermet-Guibert, J., Graupera, M., and Bilanges, B. (2010). The emerging mechanisms of isoform-specific PI3K signalling. Nat. Rev. Mol. Cell Biol. 11, 329-341.
197. Vanhaesebroeck, B., Leevers, S. J., Ahmadi, K., Timms, J., Katso, R., Driscoll, P. C., et al. (2001). Synthesis and function of 3-phosphorylated inositol lipids. Annu. Rev. Biochem. 70, 535-602.
198. Vanhaesebroeck, B., Leevers, S. J., Panayotou, G., and Waterfield, M. D. (1997a). Phosphoinositide 3-kinases: a conserved family of signal transducers. Trends Biochem. Sci. 22, 267-272.
199. Vanhaesebroeck, B., Welham, M. J., Kotani, K., Stein, R., Warne, P. H., Zvelebil, M. J., et al. (1997b). p110delta, a novel phosphoinositide 3-kinase in leukocytes. Proc. Natl. Acad. Sci. U.S.A. 94, 4330-4335.
200. Vanhaesebroeck, B., and Waterfield, M. D. (1999). Signaling by distinct classes of phosphoinisitide 3-kinases. Exp. Cell Res. 253, 239-254.
201. Vasudevan, K. M., Barbie, D. A., Davies, M. A., Rabinovsky, R., Mcnear, C. J., Kim, J. J., et al. (2009). AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer cell 16, 21-32.
202. Vivanco, I., and Sawyers, C. L. (2002). The phosphatidylinositol 3-kinase-Akt pathway in human cancer. Nat. Rev. Cancer 2, 489-501.
203. Vogt, P. K., Gymnopoulos, M., and Hart, J. R. (2009). PI 3-kinase and cancer: changing accents. Curr. Opin. Genet. Dev. 19, 12-17.
204. Voigt, P., Dorner, M. B., and Schaefer, M. (2006). Characterization of p87PIKAP, a novel regulatory subunit of phosphoinositide 3-kinase gamma that is highly expressed in heart and interacts with PDE3B. J. Biol. Chem. 281, 9977-9986.
205. Wee, S., Wiederschain, D., Maira, S.-M., Loo, A., Miller, C., Debeaumont, R., et al. (2008). PTEN-deficient cancers depend on PIK3CB. Proc. Natl. Acad. Sci. U.S.A. 105, 13057-13062.
206. Weigelt, B., and Downward, J. (2012). Genomic determinants of PI3K pathway inhibitor response in cancer. Front. Oncol. 2:109. doi: 10.3389/fonc.2012.00109
207. Weigelt, B., Warne, P. H., and Downward, J. (2011). PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs. Oncogene 30, 3222-3233.
208. Welch, H. C., Coadwell, W. J., Ellson, C. D., Ferguson, G. J., Andrews, S. R., Erdjument-Bromage, H., et al. (2002). P-Rex1, a PtdIns(3, 4, 5)P3-and Gbetagamma-regulated guanine-nucleotide exchange factor for Rac. Cell 108, 809-821.
209. Whitehead, M. A., Bombardieri, M., Pitzalis, C., and Vanhaesebroeck, B. (2012). Isoform-selective induction of human p110d PI3K expression by TNFa: identification of a new and inducible PIK3CD promoter. Biochem. J. 443, 857-867.
210. Willems, L., Tamburini, J., Chapuis, N., Lacombe, C., Mayeux, P., and Bouscary, D. (2012). PI3K and mTOR signaling pathways in cancer: new data on targeted therapies. Curr. Oncol. Rep. 14, 129-138.
211. Wood, L. D., Parsons, D. W., Jones, S., Lin, J., Sjöblom, T., Leary, R. J., et al. (2007). The genomic landscapes of human breast and colorectal cancers. Science 318, 1108-1113.
212. Xing, Y., Gerhard, B., and Hogge, D. E. (2012). Selective small molecule inhibitors of p110a and d isoforms of phosphoinosityl-3-kinase are cytotoxic to human acute myeloid leukemia progenitors. Exp. Hematol. 40, 922-933.
213. Xu, Q., Simpson, S.-E., Scialla, T. J., Bagg, A., and Carroll, M. (2003). Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood 102, 972-980.
214. Yamazaki, T., Takeda, K., Gotoh, K., Takeshima, H., Akira, S., and Kurosaki, T. (2002). Essential immunoregulatory role for BCAP in B cell development and function. J. Exp. Med. 195, 535-545.
215. Yuan, T. L., and Cantley, L. C. (2008). PI3K pathway alterations in cancer: variations on a theme. Oncogene 27, 5497-5510.
216. Zhao, L., and Vogt, P. K. (2008a). Class I PI3K in oncogenic cellular transformation. Oncogene 27, 5486-5496.
217. Zhao, L., and Vogt, P. K. (2008b). Helical domain and kinase domain mutations in p110a of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc. Natl. Acad. Sci. U.S.A. 105, 2652-2657.
218. Zhao, S., Konopleva, M., Cabreira-Hansen, M., Xie, Z., Hu, W., Milella, M., et al. (2003). Inhibition of phosphatidylinositol 3-kinase dephosphorylates BAD and promotes apoptosis in myeloid leukemias. Leukemia 18, 267-275.
219. Zhou, B. P., Liao, Y., Xia, W., Spohn, B., Lee, M. H., and Hung, M. C. (2001). Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat. Cell Biol. 3, 245-252.
220. Zhu, Q., Youn, H., Tang, J., Tawfik, O., Dennis, K., Terranova, P. F., et al. (2008). Phosphoinositide 3-OH kinase p85alpha and p110beta are essential for androgen receptor transactivation and tumor progression in prostate cancers. Oncogene 27, 4569-4579.
221. Zwaenepoel, O., Tzenaki, N., Vergetaki, K., Makrigiannakis, A., Vanhaesebroeck, B., and Papakonstanti, E. A. (2012). Functional CSF-1 receptors are located at the nuclear envelope and activated by the p110d isoform of PI 3-kinase. FASEB J. 26, 691-706.